Corona Remedies IPO Allotment Status Check Kaise Kare Online

Corona Remedies IPO allotment wait is finally over for investors. The pharmaceutical company Corona Remedies Limited finalized its IPO allotment on December 11, 2025. Investors can now check their allotment status online through NSE, BSE and Bigshare Services websites. This IPO was a 655.37 crore rupees offer for sale that opened on December 8 and closed on December 10.

The subscription numbers surprised everyone as the IPO got subscribed 137.04 times. Retail investors had very low odds but lucky investors who received allotment have hopes for listing gains. Grey market shows shares trading around 1357 rupees which indicates a 27 percent premium.

Company shares will list on both BSE and NSE exchanges on December 15, 2025. In this article we will explain how you can check your allotment status and what to expect before listing day arrives.

Corona Remedies is a branded pharmaceutical formulation company working in therapeutic areas like women’s healthcare, cardio-diabeto, pain management and urology segments. The company generates 97 percent of its revenue from the domestic market which makes it stable.

IPO price band was set between 1008 to 1062 rupees per share and minimum lot size was 14 shares meaning investors had to invest at least 14868 rupees. QIB category saw maximum demand with 278 times subscription while retail investors gave 29 times subscription. Company will not receive any proceeds from this IPO because it was a pure OFS where promoters and investors sold their stake.

Key Takeaways

• Corona Remedies IPO allotment was finalized on December 11, 2025 and investors can check status on NSE, BSE or Bigshare Services portals
• IPO received overall subscription of 137.04 times with QIB giving 278 times and retail giving 29 times subscription numbers
• Listing date is December 15, 2025 and grey market premium is around 27 percent suggesting strong listing gains ahead
• Price band was 1008 to 1062 rupees and minimum investment required was 14868 rupees for 14 shares lot
• Company operates in pharmaceutical sector focusing on women’s health and chronic therapies with 97 percent domestic revenue base
• Refund process started from December 12 and allotted shares will be credited to demat accounts soon

Also Read: Nainital Bank Recruitment 2025: 185 Vacancies for Clerk and Officer Posts – Apply Now

How To Check Corona Remedies IPO Allotment Status Online

Checking allotment status is very simple for investors. Investors can check their status using three different methods. The first method is using Bigshare Services portal which is the official registrar for this IPO. Second method is NSE website and third is BSE portal.

You will need to provide your PAN number, application number or demat account details at each platform. If you received allotment then shares will automatically get credited to your demat account. If you did not get allotment then refund process will return your money through ASBA or UPI method within 1-2 days.

To check status on Bigshare Services you need to visit ipo.bigshareonline.com/IPO_Status.html website. Here you have to select Corona Remedies IPO and then enter your PAN number, application number or DP ID details.

After filling captcha and clicking submit button your status will appear on screen. For checking on NSE you need to go to nseindia.com/products-services/ipos-allotments and select Status of IPO Allotment option. For BSE visit bseindia.com/investors/appli_check.aspx and select Equity in issue type then choose Corona Remedies and enter PAN details.

Subscription Details And Investor Response

This IPO received overwhelming response from all investor categories. Overall subscription stood at 137.04 times which is exceptional for a pure OFS offering. Qualified Institutional Buyers showed maximum interest with 278.52 times subscription rate.

Non-Institutional Investors quota got subscribed 208.88 times showing strong interest. Retail investors portion was subscribed 28.73 times which means only one out of every 29 applications received allotment. Total bids came for 62.65 crore shares while only 45.72 lakh shares were on offer. This demand supply gap shows how tough the competition was for getting allotment.

Company raised 194.86 crore rupees from anchor investors where 17 anchor investors participated before the issue opened. Promoters and investors sold their stake in this OFS including Dr Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta and investors like Chrys Capital. Post-IPO promoter holding will be around 69 percent of total equity.

Company business model is strong with 71 brands across different therapeutic areas. Women’s healthcare segment contributes 28 percent of revenue while cardio-diabeto contributes 23 percent and pain management adds 12 percent to total revenues.

Grey Market Premium And Listing Expectations

Grey market is showing Corona Remedies shares trading at 1357 rupees per share which is 295 rupees premium over upper price band of 1062 rupees. This translates to approximately 27.78 percent premium indicating strong listing gains possibility.

Market experts say demand for domestic pharma companies is high so this premium may remain stable. But remember that GMP is an unofficial indicator and not regulated by SEBI authorities. Actual listing price will depend on market conditions and overall sentiment on listing day.

Listing will happen on December 15, 2025 at 10 am on both BSE and NSE exchanges. Investors who received allotment need to decide whether they will sell on listing day or hold for long term gains. Company fundamentals are strong with EBITDA margin of 20.6 percent and consistent revenue growth track record.

Upcoming hormone manufacturing facility in Gujarat will be ready by H1 FY27 which will add future growth potential. But valuation is rich at 44x FY25 PAT and capacity utilization is already at 94-96 percent which may create some growth limitations.

Refund Process And Share Credit Timeline

Investors who did not receive allotment will get refunds starting from December 12 onwards. Investors using ASBA method will see their money automatically unblocked and UPI mandate users will receive refund within 1-2 business days.

Allotted investors will see shares credited to their demat accounts by December 12 end of day. After shares get credited to demat account you can wait till listing day to trade them.

Company shares will become tradable after listing on exchanges. Analysts are suggesting that for short term gains investors can exit on listing day but long term investors should look at company fundamentals and future plans before making decisions.

Pharma sector has tough competition but Corona Remedies domestic focus and chronic therapy portfolio provides stable revenue streams. Company has pan India distribution network and 94 percent plus capacity utilization shows strong production efficiency levels.

Company Profile And Business Model

Corona Remedies Limited is an Ahmedabad based pharmaceutical formulation company incorporated in August 2004. Company develops, manufactures and markets branded formulations covering multiple therapeutic areas for patients.

Women’s health segment is the strongest vertical with hormones, fertility treatments and pregnancy related products portfolio. Cardio-diabeto segment treats diabetes and cardiovascular conditions while pain management segment provides medicines for acute and chronic pain relief.

Company revenue model is a mix of B2B and B2C channels with strong field force and distributor network presence. Urban and semi-urban markets have strong company presence across India. Brand acquisition strategy has also been adopted by company to expand product portfolio continuously.

Manufacturing facilities are quality focused and follow all regulatory standards properly. Management team is experienced and marquee investors like Chrys Capital provide backing which adds credibility to business operations.

Tags: Corona Remedies IPO, IPO Allotment Status, Grey Market Premium, Pharmaceutical IPO, NSE BSE Listing, Stock Market Investment, IPO Investment Guide

About Author